Sirio is the leading integrated contract manufacturer for the dietary supplement industry. The company has global operations, with development and manufacturing capabilities spanning all dosage forms - including softgel, nutraceutical gummy, veggiesoft®, probiotic, tablet, powder, capsule and functional beverage.
(Yicai) Nov. 29 -- Shares of Sirio Pharma rose after the Chinese producer of nutritional health food said it plans to invest no more than USD40 million to build a factory in Thailand to refine its global supply chain and better avoid market risks.
Sirio Pharma [SHE: 300791] jumped 4.5 percent to CNY28.15 (USD3.89) apiece as of lunch break in Shenzhen today, after earlier surging by as much as 5.4 percent.
Sirio Pharma plans to buy land and construct the plant in Chonburi province, the Shantou-based firm announced late yesterday. It will set up production lines for fudge candy and packaging lines for soft and hard capsules and tablets, it added.
July 8 -- Sirio Pharma’s shares jumped after the leading Chinese contract manufacturer of dietary supplements said it will acquire an 80 percent stake in US rival Best Formulations for USD180 million.